DBV Technologies (DBVT)

Currency in USD
21.250
-0.390(-1.80%)
Closed·
21.2500.000(0.00%)
·
DBVT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
21.07021.950
52 wk Range
7.26026.185
Key Statistics
Prev. Close
21.64
Open
21.95
Day's Range
21.07-21.95
52 wk Range
7.26-26.185
Volume
193.1K
Average Vol. (3m)
323.06K
1-Year Change
189.1156%
Book Value / Share
0.84
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DBVT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
40.555
Upside
+90.85%
Members' Sentiments
Bearish
Bullish
ProTips
Stock price often moves in the opposite direction of the market

DBV Technologies News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.

Employees
117

DBV Technologies SWOT Analysis


Analyst Optimism
Discover why analysts set price targets ranging from $7.39 to $21.15, reflecting confidence in DBV's pipeline and market potential
Financial Crossroads
Delve into DBV's financial position, including its $128 million cash reserves and potential $180 million warrant exercise, as it approaches critical milestones
Market Opportunity
Explore the vast potential of the pediatric peanut allergy market, with projected peak sales exceeding $2 billion for Viaskin Peanut
Peanut Allergy Pionee
DBV Technologies leads innovation in food allergy treatment with Viaskin Peanut, a non-invasive epicutaneous immunotherapy showing promise in clinical trials
Read full SWOT analysis

DBV Technologies Earnings Call Summary for Q2/2024

  • DBV Technologies advances Viaskin Peanut trials; VITESSE Phase 3 enrollment for ages 4-7 to complete by Q3 end
  • Net loss of $60.5M in H1 2024; cash runway extended to Q1 2025 through cost-saving measures
  • FDA feedback pending on labeling approach for toddlers aged 1-3; EPITOPE trial year 3 results expected later in 2024
  • Operating expenses at $65M, including $24M non-recurring costs; cash used in operations totaled $70M
  • Company optimistic about FDA agreement on labeling; emphasizes patient experience data importance
Last Updated: 07/31/2024, 06:53 PM
Read Full Transcript

Compare DBVT to Peers and Sector

Metrics to compare
DBVT
Peers
Sector
Relationship
P/E Ratio
−8.7x−2.0x−0.5x
PEG Ratio
−0.880.310.00
Price / Book
7.5x3.1x2.6x
Price / LTM Sales
225.6x3.9x3.2x
Upside (Analyst Target)
119.8%25.8%47.6%
Fair Value Upside
Unlock14.0%6.1%Unlock

Analyst Ratings

5 Buy
0 Hold
1 Sell
Ratings:
6 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 40.555
(+90.85% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Goldman Sachs
Sell5.81-72.66%7.94MaintainApr 09, 2026
Cantor Fitzgerald
Buy48.00+125.88%-MaintainMar 30, 2026
Cantor Fitzgerald
Buy48.00+125.88%-MaintainMar 27, 2026
Citizens
Buy47.00+121.18%45.00MaintainMar 27, 2026
Citizens
Buy45.00+111.76%-MaintainMar 03, 2026

Earnings

Latest Release
Mar 26, 2026
EPS / Forecast
-0.24 / --
Revenue / Forecast
645K / --
EPS Revisions
Last 90 days

DBVT Income Statement

People Also Watch

8.150
INNV
-0.24%
10.12
NOAH
+1.10%
88.96
KYMR
-1.01%
1.0600
BFRI
-2.75%

FAQ

What Is the DBV Technologies (DBVT) Stock Price Today?

The DBV Technologies stock price today is 21.250 USD.

What Stock Exchange Does DBV Technologies Trade On?

DBV Technologies is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for DBV Technologies?

The stock symbol for DBV Technologies is "DBVT."

What Is the DBV Technologies Market Cap?

As of today, DBV Technologies market cap is 1.270B USD.

What Is DBV Technologies's Earnings Per Share (TTM)?

The DBV Technologies EPS (TTM) is -1.053.

From a Technical Analysis Perspective, Is DBVT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has DBV Technologies Stock Split?

DBV Technologies has split 2 times.

How Many Employees Does DBV Technologies Have?

DBV Technologies has 117 employees.

What is the current trading status of DBV Technologies (DBVT)?

As of Apr 15, 2026, DBV Technologies (DBVT) is trading at a price of 21.250 USD, with a previous close of 21.640 USD. The stock has fluctuated within a day range of 21.070 USD to 21.950 USD, while its 52-week range spans from 7.260 USD to 26.185 USD.

What Is DBV Technologies (DBVT) Price Target According to Analysts?

The average 12-month price target for DBV Technologies is 40.555 USD, with a high estimate of 52.22130471 USD and a low estimate of 5.86174354 USD. 5 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +90.85% Upside potential.

What Is the DBVT Premarket Price?

DBVT's last pre-market stock price is 21.980 USD. The pre-market share volume is 12,870.000, and the stock has decreased by 0.340, or 1.570%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.